Novo Nordisk's Buyback Buffer Against a Perfect Storm

Novo Nordisk launches a massive share buyback as it faces its first revenue decline in 25 years, intense competition from Eli Lilly, and key FDA decisions ahead.

Novo Nordisk is deploying billions of kroner to support its share price, a defensive financial maneuver that underscores the unprecedented operational challenges facing the Danish pharmaceutical giant. The company is bracing for its first revenue decline in 25 years, even as it intensifies a high-stakes clinical and commercial battle with rival Eli Lilly.

A Financial Lifeline in Rough Seas

The scale of the support is substantial. As part of a 12-month, 15-billion-kroner share repurchase program, the company has already bought back nearly 10 million of its own B shares since early February, spending approximately DKK 2.59 billion. These transactions now represent a 0.6 percent stake in the company's share capital. This aggressive buyback is a direct response to severe market pressure: the stock has plummeted 46 percent over the past twelve months and currently trades around 29 percent below its level at the start of the year, hovering at EUR 32.12 and remaining well below its 200-day moving average.

The Gathering Storm Clouds

This financial intervention comes as Novo Nordisk confronts a confluence of negative forces. Management forecasts a currency-adjusted sales drop of 5 to 13 percent for 2026. Two primary US policy changes are driving this decline: the Most-Favored-Nation price agreement with the US government and restricted Medicaid reimbursement for obesity treatments. These headwinds are squeezing margins and creating a fundamentally weaker revenue environment.

Competition is another mounting pressure. Eli Lilly now commands over 60 percent of the US market for weight-loss injections. In a strategic counterpunch just one day after the FDA approved Lilly's oral drug Orforglipron, Novo Nordisk released comparative data from its ORION study. The research, presented at the Obesity Medicine Association's annual meeting, suggests an advantage for its oral Wegovy (semaglutid 25 mg) over Orforglipron 36 mg, showing a weight loss benefit of roughly 3.2 percentage points under real-world conditions.

The data also highlighted a significant tolerability gap. The odds ratio for discontinuing treatment due to gastrointestinal side effects was 13.9 times higher for Orforglipron. A separate patient survey (OPTIC) of 800 US adults found 84 percent preferred a treatment profile similar to oral semaglutid. Analysts note, however, that the indirect study design leaves room for population differences, and direct head-to-head trials are still lacking.

The Autumn Catalyst

With the operational landscape under strain, investor focus has shifted decisively to the company's pipeline. The next major catalyst is the anticipated FDA decision on CagriSema, a combination of cagrilintid and semaglutid submitted for obesity treatment. The agency's verdict is expected around the turn of the year 2026/2027, with some analysts pinpointing October 2026. The drug showed promise in Phase 3 trials, achieving an average weight loss of 23 percent.

The upcoming first-quarter report in May will provide the market's first clear look at margin development under the new US pricing regime, setting the tone for the stock's trajectory in the months leading to the FDA decision. Until CagriSema's fate is known, the structural pressure from the weak sales environment is likely to persist, leaving Novo Nordisk's massive share buyback as a critical, but temporary, buffer against the storm.